Skip to content
FrontierPicks

Watching

NVO · Novo-Nordisk A/S

Conviction · Low · more likely to lag the S&P 500 over the next three months

Wrong if: a daily close above $44.88

Theme leader Catalyst · GLP-1 & obesity drugs

Note written ·

Price against the kill line

9.3% clear of its kill line on the 17 November 2026 close.

How to read this

This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.

The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.

The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides

NVONovo-Nordisk A/S
$44.88
$40.70
9.3%well clear

Three months against the kill line

NVO daily closes from 19 August 2026 to 17 November 2026, last $40.70, against its kill line: a daily close above $44.88. 19 August 2026: $46.4820 August 2026: $46.1421 August 2026: $46.7424 August 2026: $46.9225 August 2026: $48.6626 August 2026: $47.1927 August 2026: $46.2628 August 2026: $45.6131 August 2026: $45.331 September 2026: $45.122 September 2026: $46.773 September 2026: $47.514 September 2026: $46.608 September 2026: $45.169 September 2026: $44.5610 September 2026: $44.0111 September 2026: $43.0714 September 2026: $43.4515 September 2026: $42.5316 September 2026: $41.7117 September 2026: $43.1918 September 2026: $43.2421 September 2026: $39.8022 September 2026: $39.4023 September 2026: $38.1724 September 2026: $38.6225 September 2026: $38.8028 September 2026: $38.7129 September 2026: $38.3130 September 2026: $37.911 October 2026: $37.402 October 2026: $37.325 October 2026: $37.546 October 2026: $37.537 October 2026: $38.268 October 2026: $38.189 October 2026: $38.6412 October 2026: $38.5813 October 2026: $38.0614 October 2026: $38.1215 October 2026: $39.2216 October 2026: $38.8319 October 2026: $38.4220 October 2026: $39.3521 October 2026: $39.0622 October 2026: $39.4323 October 2026: $39.0526 October 2026: $39.1327 October 2026: $38.6728 October 2026: $38.2929 October 2026: $39.1430 October 2026: $40.002 November 2026: $40.453 November 2026: $40.194 November 2026: $42.185 November 2026: $40.306 November 2026: $40.319 November 2026: $41.3810 November 2026: $40.7011 November 2026: $41.0912 November 2026: $40.6513 November 2026: $41.6316 November 2026: $41.6017 November 2026: $40.70

Daily closes, to . Red: the kill line, a daily close above $44.88, set on 14 November 2026. The shares are down 12.4% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.

Kill line

A daily close above $44.88, the 17 August 2026 close where the three-month decline began and above the 200-day moving average, which would show the shares leading; or a 2027 outlook that guides adjusted sales growth at constant exchange rates despite the January list-price cuts.

Research onlyNot in the portfolio.

Catalyst

The portfolio's record →

The business · as of

Novo Nordisk sells diabetes and obesity medicines, chiefly Ozempic and Wegovy as injections and as a pill, plus drugs for rare blood and hormone disorders. It sells to wholesalers, pharmacies, insurers and governments worldwide. Third-quarter 2026 sales were DKK 79,195 million, according to its 6-K of 4 November 2026.

What is changing, and what follows · as of

What is changing now
On 4 November 2026 Novo Nordisk raised its 2026 outlook to adjusted sales growth of minus 2% to plus 2% at constant exchange rates. It also announced US list-price cuts of about 50% for Wegovy and 35% for Ozempic, effective 1 January 2027.
What follows for the company
Free-cash-flow guidance rose to DKK 60–70 billion and capital spending is around DKK 50 billion. Third-quarter charges were DKK 8.7 billion, including DKK 4.1 billion for scaling down the manufacturing network.
What follows for its customers, suppliers and competitors
Eli Lilly (LLY) is widening distribution through Hims & Hers (HIMS). Pfizer (PFE) is funding a monthly GLP-1 drug with Blackstone (BX). Insurers such as CVS Health (CVS) face lower list prices from 1 January 2027.

What the price assumes · as of

No US filed multiples exist because Novo Nordisk reports under international accounting standards on Form 6-K. At the 13 November 2026 close of $41.63, 35.1% below the January high, the price rests on flat 2026 guidance of minus 2% to plus 2% adjusted sales growth and free cash flow of DKK 60–70 billion (6-K, 4 November 2026). It assumes 2027 volume growth offsets the January list-price cuts.

Key figures from the filings · Health Care

Filed figures are not available: no quarterly report in US GAAP with the SEC (a foreign filer reports on Form 20-F or 40-F).

All filed numbers

What Novo-Nordisk A/S reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Short interest (FINRA, settled 30 October 2026, published 10 November 2026): the share of shares outstanding is not available, 4.0 days of average trading to cover, +2.3% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date
Window Bought Sold
90 days Not available yet Not available yet
12 months Not available yet Not available yet

Linked companies · as of

Customers:
CVS
Competitors:
LLY, PFE, VANI

The thesis

Novo Nordisk's shares are more likely to lag than to lead the S&P 500 over the next three months. The third-quarter beat of 4 November 2026 is real. But on 1 January 2027 US list prices for Wegovy fall about 50% and for Ozempic about 35%, and the 2027 outlook at the full-year report, expected in early February 2027, will show whether volume growth makes up for those cuts.

The rating is Low because the next dated events test pricing more than volume. On 4 November 2026 the company raised its 2026 outlook for the third time, to adjusted sales and adjusted operating profit growth of minus 2% to plus 2% at constant exchange rates (CER). The new range is still flat at its midpoint. Jefferies kept a Hold rating and a DKK 275 target on 4 November 2026. It estimated that about DKK 2 billion of favourable gross-to-net pricing adjustments helped the quarter. Gross-to-net adjustments are the gap between list prices and the prices actually received after rebates.

The FDA decision on CagriSema, which the company expects by the end of 2026, is the main event that could change the call before February.

Bullish and bearish views on Novo-Nordisk A/S

The bull case on Novo-Nordisk A/S (NVO), in brief: third quarter beat and a third raise. The bear case: price is falling faster than volume grows.

Bull case

  • Third quarter beat and a third raise. Adjusted sales were DKK 79,195 million in the third quarter of 2026, up 4% at CER. Adjusted operating profit was DKK 31,720 million, up 27% at CER (company 6-K, 4 November 2026). Finviz reported on 4 November 2026 that both figures were about 8% and 10% above the Visible Alpha consensus.
  • Wegovy pill is adding volume. The Wegovy pill sold DKK 5,394 million in the third quarter (6-K, 4 November 2026). The company expects it in more than 20 markets in 2027.
  • Cash generation stepped up. The company raised its 2026 free-cash-flow guidance to DKK 60–70 billion from DKK 45–55 billion on 4 November 2026. It had repurchased 42,604,179 B shares as of 6 November 2026 (company announcement, 9 November 2026).
  • Obesity pipeline and launch ready. CagriSema was filed with the FDA on 18 December 2025. The 4 November 2026 report targets a US launch in early 2027, subject to approval.
  • Growth outside obesity. The European Commission approved the hemophilia A drug Frehemgo (denecimig) on 13 November 2026, with a US launch expected in the first half of 2027. On 13 November 2026 the company also filed the sickle cell drug etavopivat with the FDA and the European Medicines Agency.

Bear case

  • Price is falling faster than volume grows. Injectable Wegovy sales fell 2% at CER to DKK 20,407 million and Ozempic fell 5% to DKK 29,706 million in the third quarter (6-K, 4 November 2026). US sales grew only 1% at CER, to DKK 41,880 million.
  • Deep US list-price cuts from 1 January 2027. The company plans to cut Wegovy's US list price by about 50% and Ozempic's by about 35%, to a wholesale acquisition cost of $675 each (Finviz, 4 November 2026).
  • Part of the beat was pricing true-ups. Jefferies estimated on 4 November 2026 that, without about DKK 2 billion of gross-to-net benefit, the sales beat would have been about 5% instead of 8%. On that basis injectable Wegovy would likely have missed expectations.
  • Competition is widening. Eli Lilly began offering its obesity drugs through Hims & Hers, according to news on 6 November 2026. On 11 November 2026 Pfizer and Blackstone Life Sciences signed a deal under which Blackstone will pay up to $1.5 billion of development costs for Pfizer's monthly GLP-1 drug berobenatide.
  • Class-wide safety label. On 9 November 2026 the FDA required all GLP-1 drugs, Wegovy and Ozempic included, to warn of a potential risk of the eye condition nonarteritic anterior ischemic optic neuropathy.
  • Charges and restructuring. Third-quarter reported operating profit fell 9% at CER to DKK 23,011 million after DKK 8.7 billion of impairments. These included DKK 4.6 billion for ziltivekimab and DKK 4.1 billion for scaling down the manufacturing network (6-K, 4 November 2026).

Price setup

The American depositary shares closed at $41.63 on 13 November 2026. That is 35.1% below the 52-week intraday high of $64.16 set on 23 January 2026, and above the 52-week closing low of $35.29 on 30 March 2026. On adjusted daily closes the shares sit above the 50-day moving average of $40.09 and below the 200-day moving average of $42.71, both as of 13 November 2026. The three-month change is minus 7.2%.

The raised outlook barely moved the shares. Over the week after the report they closed between $40.31 on 6 November 2026 and $41.63 on 13 November 2026. A close back above the 200-day moving average would be the first sign that buying is outlasting the pricing worries.

The three-month decline is small for the market. Across liquid US stocks the standard deviation of 63-session returns was 27% in 2026.

Catalysts ahead

  • ~31 December 2026 (est.): FDA decision on CagriSema for weight management, expected by the company by the end of 2026. Approval would support the early-2027 US launch and a new obesity product before the list-price cuts. A delay would remove the main positive event before February.
  • 1 January 2027: US list-price cuts take effect: about 50% for Wegovy and 35% for Ozempic. This is the start of the pricing reset. Early-2027 prescription and net-price trends will show whether volume makes up for the lower prices.
  • ~4 February 2027 (est.): Full-year 2026 results and the first 2027 outlook. The 2027 sales and operating profit guidance settles whether volume growth makes up for the price cuts. A growth outlook would contradict the lag call.

What would change the view

A daily close above $44.88, the 17 August 2026 close where the three-month decline began and above the 200-day moving average, which would show the shares leading; or a 2027 outlook that guides adjusted sales growth at constant exchange rates despite the January list-price cuts.

What it trades with

The shares trade with US obesity-drug news and with Eli Lilly (LLY). Both companies' drugs carry the 9 November 2026 FDA eye-risk label. Their analyst views have split: Jefferies raised its Lilly target to a Street-high $1,700 on 9 November 2026, five days after holding Novo at Hold with a DKK 275 target.

US drug-pricing policy affects Novo directly. The company says its 2026 outlook assumes lower realised prices, including under its most-favoured-nation pricing agreement with the US government. NVO is a US listing of a Danish company that reports in Danish kroner, so the dollar-to-krone exchange rate also moves the price apart from the business.

The evidence, claim by claim (8)
  1. Third-quarter 2026 sales were DKK 79,195 million, up 4% at constant exchange rates. US sales were DKK 41,880 million, up 1%, and International Operations sales were DKK 37,315 million, up 8%. Novo Nordisk Q3 2026 report, Form 6-K · as of
  2. Third-quarter 2026 adjusted operating profit was DKK 31,720 million, up 27% at constant exchange rates. Reported operating profit fell 9% to DKK 23,011 million after DKK 8.7 billion of impairments. Novo Nordisk Q3 2026 report, Form 6-K · as of
  3. The 2026 outlook was raised to adjusted sales and operating profit growth of minus 2% to plus 2% at constant exchange rates, from minus 6% to 0%. Free-cash-flow guidance was raised to DKK 60–70 billion. Novo Nordisk Q3 2026 report, Form 6-K · as of
  4. In the third quarter of 2026 the Wegovy pill sold DKK 5,394 million, injectable Wegovy fell 2% to DKK 20,407 million, and Ozempic fell 5% to DKK 29,706 million, at constant exchange rates. Novo Nordisk Q3 2026 report, Form 6-K · as of
  5. Novo Nordisk plans to cut US list prices for Wegovy by about 50% and Ozempic by about 35% from 1 January 2027, to a wholesale acquisition cost of $675 each. Finviz news report, 4 November 2026 · as of
  6. Jefferies kept a Hold rating and a DKK 275 target. It estimated about DKK 2 billion of favourable gross-to-net pricing benefit in the third quarter. Jefferies note cited by Finviz, 4 November 2026 · as of
  7. Novo Nordisk had repurchased 42,604,179 B shares under its share repurchase program as of 6 November 2026. Novo Nordisk company announcement, 9 November 2026 · as of
  8. The European Commission granted marketing authorization for the hemophilia A drug Frehemgo (denecimig). Novo Nordisk company announcement, 13 November 2026 · as of

Sources

Related · shared themes

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X